Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 93.3% in February

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLYGet Free Report) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 100 shares, a drop of 93.3% from the January 31st total of 1,500 shares. Based on an average daily volume of 3,300 shares, the days-to-cover ratio is currently 0.0 days.

Clinuvel Pharmaceuticals Trading Up 1.9 %

Shares of OTCMKTS:CLVLY traded up $0.17 during midday trading on Wednesday, reaching $9.17. The company had a trading volume of 925 shares, compared to its average volume of 3,804. Clinuvel Pharmaceuticals has a 1-year low of $8.76 and a 1-year high of $13.97. The company has a fifty day simple moving average of $10.29 and a two-hundred day simple moving average of $10.68.

About Clinuvel Pharmaceuticals

(Get Free Report)

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

Recommended Stories

Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.